Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
Top Cited Papers
- 9 October 2014
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 371 (15), 1392-1406
- https://doi.org/10.1056/nejmoa1407963
Abstract
In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perindopril and indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, did not. We now report results of the 6-year post-trial follow-up. We invited surviving participants, who had previously been assigned to perindopril–indapamide or placebo and to intensive or standard glucose control (with the glucose-control comparison extending for an additional 6 months), to participate in a post-trial follow-up evaluation. The primary end points were death from any cause and major macrovascular events. The baseline characteristics were similar among the 11,140 patients who originally underwent randomization and the 8494 patients who participated in the post-trial follow-up for a median of 5.9 years (blood-pressure–lowering comparison) or 5.4 years (glucose-control comparison). Between-group differences in blood pressure and glycated hemoglobin levels during the trial were no longer evident by the first post-trial visit. The reductions in the risk of death from any cause and of death from cardiovascular causes that had been observed in the group receiving active blood-pressure–lowering treatment during the trial were attenuated but significant at the end of the post-trial follow-up; the hazard ratios were 0.91 (95% confidence interval [CI], 0.84 to 0.99; P=0.03) and 0.88 (95% CI, 0.77 to 0.99; P=0.04), respectively. No differences were observed during follow-up in the risk of death from any cause or major macrovascular events between the intensive-glucose-control group and the standard-glucose-control group; the hazard ratios were 1.00 (95% CI, 0.92 to 1.08) and 1.00 (95% CI, 0.92 to 1.08), respectively. The benefits with respect to mortality that had been observed among patients originally assigned to blood-pressure–lowering therapy were attenuated but still evident at the end of follow-up. There was no evidence that intensive glucose control during the trial led to long-term benefits with respect to mortality or macrovascular events. (Funded by the National Health and Medical Research Council of Australia and others; ADVANCE-ON ClinicalTrials.gov number, NCT00949286.)Keywords
This publication has 14 references indexed in Scilit:
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetesKidney International, 2013
- Persistence of Mortality Reduction After the End of Randomized Therapy in Clinical Trials of Blood Pressure–Lowering MedicationsHypertension, 2010
- Intensive Blood-Pressure Control in Hypertensive Chronic Kidney DiseaseThe New England Journal of Medicine, 2010
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 DiabetesThe New England Journal of Medicine, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Paget's Disease of the MandibleThe New England Journal of Medicine, 2008
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesThe New England Journal of Medicine, 2005
- Multiplicity in randomised trials I: endpoints and treatmentsThe Lancet, 2005
- Study Rationale and Design of ADVANCE: Action in Diabetes and Vascular disease - preterax and diamicron MR controlled evaluationDiabetologia, 2001